We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $3.5B
1-Year Est. Return 1,165.83%
This Fund
S&P 500
This Quarter Est. Return
+54.43%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$902M
AUM Growth
+$223M
Cap. Flow
+$52.2M
Cap. Flow %
5.79%
Top 10 Hldgs %
61.32%
Holding
31
New
5
Increased
2
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$34.8M
2
TRML
Tourmaline Bio
TRML
+$20.2M
3
ABVX
Abivax
ABVX
+$11.2M
4
VTGN icon
VistaGen Therapeutics
VTGN
+$10.1M
5
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$6.7M

Top Sells

Rank Stock Value
1
TSHA icon
Taysha Gene Therapies
TSHA
+$16.3M
2
IMVT icon
Immunovant
IMVT
+$12.9M
3
MRUS
Merus
MRUS
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCCC icon
26
C4 Therapeutics
CCCC
$397M
$7.21M 0.8%
1,276,574
– –
TSHA icon
27
Taysha Gene Therapies
TSHA
$1.59B
$5.16M 0.57%
2,912,861
-8,198,250
-74% -$16.3M
VTYX
28
DELISTED
Ventyx Biosciences
VTYX
$2.01M 0.22%
815,724
– –
KOD icon
29
Kodiak Sciences
KOD
$2.62B
$815K 0.09%
+267,941
New +$596K
IMVT icon
30
Immunovant
IMVT
$8.23B
– –
-334,853
Closed -$12.9M
MRUS
31
DELISTED
Merus
MRUS
– –
-300,000
Closed -$7.07M
1
2

Similar funds

DILIC
Dai-ichi Life Insurance Company Tokyo, Japan $3.49B AUM 27.28% 1-Year Est. Return
KCM
Kedalion Capital Management London, United Kingdom $3.48B AUM 17.74% 1-Year Est. Return
ACM
Aquatic Capital Management Chicago, Illinois $3.48B AUM 24.9% 1-Year Est. Return
BCP
BDT Capital Partners Chicago, Illinois $3.51B AUM 31.02% 1-Year Est. Return
ACA
Anchor Capital Advisors Boston, Massachusetts $3.51B AUM 16.99% 1-Year Est. Return
MSC
MUFG Securities (Canada) New York $3.48B AUM 45.13% 1-Year Est. Return
TH
TCTC Holdings Dallas, Texas $3.51B AUM 30.71% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return

TCG Crossover Management's Q4 2023 Portfolio in Review

As of Q4 2023, TCG Crossover Management held 31 positions worth $902M, up 33% from $679M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

TCG Crossover Management deployed $52.2M of net new capital in Q4 2023, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was Tourmaline Bio: 1,007,902 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Taysha Gene Therapies, an estimated $16.3M trimmed.

  • TCG Crossover Management's largest Q4 2023 buy was Tourmaline Bio: 1,007,902 shares worth $26.4M.
  • TCG Crossover Management added most to Structure Therapeutics in Q4 2023, an estimated $34.8M increase.
  • TCG Crossover Management's biggest Q4 2023 reduction was Taysha Gene Therapies, cutting an estimated $16.3M.
  • TCG Crossover Management fully exited Immunovant in Q4 2023, selling an estimated $12.9M.
  • TCG Crossover Management's ten largest holdings make up 61% of its $902M portfolio in Q4 2023.
  • TCG Crossover Management opened 5 new positions and closed 2 in Q4 2023.
  • TCG Crossover Management's portfolio value rose 33% quarter-over-quarter to $902M.

Based on TCG Crossover Management's 13F filing for Q4 2023, filed 14 Feb 2024.